FGF21 and its analogues are currently being investigated in clinical trials for the treatment of obesity, type 2 diabetes, and fatty liver disease [27, 28], while the clinical potential of rGDF15 for obesity treatment is also being explored [29]. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.